Literature DB >> 21178490

Ebolavirus VP35 is a multifunctional virulence factor.

Daisy W Leung1, Kathleen C Prins, Christopher F Basler, Gaya K Amarasinghe.   

Abstract

Ebola virus (EBOV) is a member of the filoviridae family that causes severe hemorrhagic fever during sporadic outbreaks, and no approved treatments are currently available. The multifunctional EBOV VP35 protein facilitates immune evasion by antagonizing antiviral signaling pathways and is important for viral RNA synthesis. In order to elucidate regulatory mechanisms and to develop countermeasures, we recently solved the structures of the Zaire and Reston EBOV VP35 interferon inhibitory domain (IID) in the free form and of the Zaire EBOV VP35 IID bound to dsRNA. Together with biochemical, cell biological, and virological studies, our structural work revealed that distinct regions within EBOV VP35 IID contribute to virulence through host immune evasion and viral RNA synthesis. Here we summarize our recent structural and functional studies and discuss the potential of multifunctional Ebola VP35 as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178490      PMCID: PMC3061251          DOI: 10.4161/viru.1.6.12984

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  39 in total

1.  Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles.

Authors:  Reed F Johnson; Sarah E McCarthy; Peter J Godlewski; Ronald N Harty
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

Authors:  Zongdi Feng; Melissa Cerveny; Zhipeng Yan; Bin He
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

3.  Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.

Authors:  Amy L Hartman; Jason E Dover; Jonathan S Towner; Stuart T Nichol
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence.

Authors:  John C Kash; Elke Mühlberger; Victoria Carter; Melanie Grosch; Olivia Perwitasari; Sean C Proll; Matthew J Thomas; Friedemann Weber; Hans-Dieter Klenk; Michael G Katze
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Reed S Shabman; Mina Farahbakhsh; Kathleen C Prins; Dominika M Borek; Tianjiao Wang; Elke Mühlberger; Christopher F Basler; Gaya K Amarasinghe
Journal:  J Mol Biol       Date:  2010-04-24       Impact factor: 5.469

Review 6.  The chase for the RIG-I ligand--recent advances.

Authors:  Martin Schlee; Gunther Hartmann
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

7.  Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling.

Authors:  Washington B Cárdenas; Yueh-Ming Loo; Michael Gale; Amy L Hartman; Christopher R Kimberlin; Luis Martínez-Sobrido; Erica Ollmann Saphire; Christopher F Basler
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.

Authors:  Kathleen C Prins; Sebastien Delpeut; Daisy W Leung; Olivier Reynard; Valentina A Volchkova; St Patrick Reid; Parameshwaran Ramanan; Washington B Cárdenas; Gaya K Amarasinghe; Viktor E Volchkov; Christopher F Basler
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

9.  VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice.

Authors:  Sven Enterlein; Kelly L Warfield; Dana L Swenson; David A Stein; Jeffery L Smith; C Scott Gamble; Andrew D Kroeker; Patrick L Iversen; Sina Bavari; Elke Mühlberger
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Authors:  Thomas W Geisbert; Amy C H Lee; Marjorie Robbins; Joan B Geisbert; Anna N Honko; Vandana Sood; Joshua C Johnson; Susan de Jong; Iran Tavakoli; Adam Judge; Lisa E Hensley; Ian Maclachlan
Journal:  Lancet       Date:  2010-05-29       Impact factor: 79.321

View more
  24 in total

1.  Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Authors:  Megan R Edwards; Gai Liu; Chad E Mire; Suhas Sureshchandra; Priya Luthra; Benjamin Yen; Reed S Shabman; Daisy W Leung; Ilhem Messaoudi; Thomas W Geisbert; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

2.  Ebola virus VP35 has novel NTPase and helicase-like activities.

Authors:  Ting Shu; Tianyu Gan; Peng Bai; Xiaotong Wang; Qi Qian; Hui Zhou; Qi Cheng; Yang Qiu; Lei Yin; Jin Zhong; Xi Zhou
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

3.  Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism.

Authors:  Shridhar Bale; Jean-Philippe Julien; Zachary A Bornholdt; Alexander S Krois; Ian A Wilson; Erica Ollmann Saphire
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

4.  Ebola virus VP35 interaction with dynein LC8 regulates viral RNA synthesis.

Authors:  Priya Luthra; David S Jordan; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

5.  Structural Insight into Nucleoprotein Conformation Change Chaperoned by VP35 Peptide in Marburg Virus.

Authors:  Baocheng Liu; Shishang Dong; Guobang Li; Wenming Wang; Xiang Liu; Yantong Wang; Cheng Yang; Zihe Rao; Yu Guo
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

6.  Ebola Virus Inclusion Body Formation and RNA Synthesis Are Controlled by a Novel Domain of Nucleoprotein Interacting with VP35.

Authors:  Tsuyoshi Miyake; Charlotte M Farley; Benjamin E Neubauer; Thomas P Beddow; Thomas Hoenen; Daniel A Engel
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

7.  The ebolavirus VP24 interferon antagonist: know your enemy.

Authors:  Adrianna P P Zhang; Dafna M Abelson; Zachary A Bornholdt; Tong Liu; Virgil L Woods; Erica Ollmann Saphire
Journal:  Virulence       Date:  2012-08-15       Impact factor: 5.882

8.  Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.

Authors:  Parameshwaran Ramanan; Megan R Edwards; Reed S Shabman; Daisy W Leung; Ariel C Endlich-Frazier; Dominika M Borek; Zbyszek Otwinowski; Gai Liu; Juyoung Huh; Christopher F Basler; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

9.  Ebola Virus Replication Stands Out.

Authors:  Wenjie Wang; Chao Wu; Gaya K Amarasinghe; Daisy W Leung
Journal:  Trends Microbiol       Date:  2019-05-30       Impact factor: 17.079

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.